Blood Adv: Vido bead monoantigene can prevent isogenetic hematopoietic stem cell transplantation after transplant anti-host disease.

Acute graft anti-host disease (aGVHD) remains an important complication of allogen hematopoietic stem cell transplantation (allo-HSCT).
Vedolizumab can help prevent aGVHD by inhibiting the migration of childish and active lymphocytes to intestinal-related lymphatic tissue and the intrinsic layer.
We conducted a phase 1b, open label, dose determination study in adults receiving hematopoietic stem cell transplantation to assess vedolizumab's tolerance, safety and pharmacogenetics, as well as its effectiveness in reducing aGVHD, the results of which were published online in Blod Adv.
results, IV vedolizumab was given on the first, 13th, and 42nd days of alllo-HSCT, starting at 75 mg, with dose upgrades under the guidance of tolerance and pharmacodynamics.
a total of 24 participants were grouped and dose-limiting toxicity was not observed in the 75 mg queue (n s 3) or the dose-upgraded 300 mg queue (n s 21).
8 participants had adverse treatment events associated with vedolizumab.
, there were four deaths in the 12 months following allo-HSCT.
participants in the 75-mg queue showed improvedGlucksberg II to IV aGVHD 100 days after alllo-HSCT.
300mg queue, 4 participants (19.0%) developed level II to LEVEL IV aGVHD within 100 days of alllo-HSCT, including 3 participants developed stage 1 aGVHD in the lower intestine.
300 mg as a aGVHD prevention tolerance is good, the overall and lower intestine aGVHD occurrence rate is very low.
, these findings support further evaluation of vedolizumab in this patient group.
.